SCHEMBL12650951

SCHEMBL12650951

CCCCCNC(=O)C1CCCCC1C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.65
NAAA Q02083 1/20 0.61
TAAR1 Q96RJ0 2/20 0.54
EPHX1 P07099 4/20 0.51
PRCP P42785 2/20 0.51
EPHX2 P34913 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12674200 0.98 NAAA (0.64) POLBNAAAEPHX1PRCPEPHX2
SCHEMBL1527321 0.98 NAAA (0.64) POLBNAAAEPHX1PRCPEPHX2
SCHEMBL16139260 0.98 NAAA (0.64) POLBNAAAEPHX1PRCPEPHX2
SCHEMBL1527320 0.98 NAAA (0.64) POLBNAAAEPHX1PRCPEPHX2
SCHEMBL10173738 0.95 POLB (0.58) POLBNAAATAAR1
SCHEMBL23285251 0.91 POLB (0.55) POLBNAAATAAR1PRCP
SCHEMBL27000233 0.84 GRM4 (0.56) POLBTAAR1EPHX1
SCHEMBL8355991 0.83 TAAR1 (0.54) POLBTAAR1
SCHEMBL10174302 0.83 TAAR1 (0.50) POLBTAAR1
SCHEMBL16141270 0.82 TAAR1 (0.52) POLBTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021220920-A1 METHOD FOR PRODUCING SURFACE-MODIFIED METAL OXIDE MICROPARTICLES, SURFACE-MODIFIED METAL OXIDE MICROPARTICLES, SURFACE-MODIFIED METAL OXIDE MICROPARTICLE DISPERSION, SOLID PRODUCT, METHOD FOR PRODUCING SURFACE-MODIFIED METAL OXIDE MICROPARTICLE DISPERSION, AND METHOD FOR PRODUCING SOLID PRODUCT 東京応化工業株式会社 (JP) 2021-11-04 WO disclosed
US-RE43298-E1 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2012-04-03 US disclosed
US-20110117057-A1 NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS SCHERING CORPORATION (US) 2011-05-19 US disclosed
US-7595299-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2009-09-29 US disclosed
US-7592316-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2009-09-22 US disclosed
US-20070232549-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION 2007-10-04 US disclosed
US-7244721-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2007-07-17 US disclosed
US-20070032433-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. 2007-02-08 US disclosed
US-7169760-B2 Peptides as NS3-serine protease inhibitors of hepatitis C virus SCHERING CORPORATION (US) 2007-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232549-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus HPN, TMPRSS15, VIP POLB 4407/4885NAAA 1690/4885TAAR1 4617/4885
US-20110117057-A1 NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS HPN, TMPRSS15, VIP POLB 4407/4885NAAA 1690/4885TAAR1 4617/4885
US-20070032433-A1 Novel peptides as NS3-serine protease inhibitors of hepatitis C virus HPN, TMPRSS15, VIP POLB 4407/4885NAAA 1690/4885TAAR1 4617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.